2022 - Research.com Immunology in France Leader Award
His primary scientific interests are in Hepatitis C virus, Virology, Hepatitis C, Immunology and Ribavirin. His research investigates the connection with Hepatitis C virus and areas like Interferon which intersect with concerns in RNA-dependent RNA polymerase. His Virology research is multidisciplinary, incorporating perspectives in RNA and Antibody.
His Hepatitis C research incorporates elements of Voxilaprevir, Serology, Drug development and Polymerase chain reaction. His research investigates the connection between Immunology and topics such as Liver disease that intersect with issues in Interferon alfa, Pegylated Interferon Alfa and Hepatocellular carcinoma. His Ribavirin research integrates issues from Gastroenterology and Internal medicine.
Virology, Hepatitis C virus, Immunology, Hepatitis C and Internal medicine are his primary areas of study. Virology is closely attributed to Genotype in his study. Hepatitis C virus is often connected to Interferon in his work.
Many of his studies on Immunology apply to Liver disease as well. His work carried out in the field of Hepatitis C brings together such families of science as Intensive care medicine, Viral replication and Hepatitis. His research in Internal medicine tackles topics such as Gastroenterology which are related to areas like Fibrosis.
His scientific interests lie mostly in Virology, Hepatitis C virus, Internal medicine, Hepatitis C and Genotype. His work is dedicated to discovering how Virology, Direct acting are connected with Antiviral therapy and other disciplines. As part of one scientific family, Jean-Michel Pawlotsky deals mainly with the area of Hepatitis C virus, narrowing it down to issues related to the Serum samples, and often Serology.
His Internal medicine research is multidisciplinary, incorporating elements of Daclatasvir, Ribavirin, Sofosbuvir, Oncology and Gastroenterology. He combines subjects such as Pibrentasvir, Glecaprevir, Hepatitis, Voxilaprevir and Hepacivirus with his study of Hepatitis C. The concepts of his Genotype study are interwoven with issues in Genome and Deep sequencing.
Jean-Michel Pawlotsky mainly focuses on Hepatitis C virus, Hepatitis C, Virology, Internal medicine and Ribavirin. His Hepatitis C virus research incorporates elements of Chronic liver disease, Direct acting, Antiviral therapy and Genotype. Jean-Michel Pawlotsky has included themes like Liver disease, Hepatitis B, Paritaprevir and Intensive care medicine in his Hepatitis C study.
His study in the field of Hepacivirus, NS5A and Viral load is also linked to topics like Clinical performance. Immunology covers Jean-Michel Pawlotsky research in Hepacivirus. His Internal medicine research includes elements of Pibrentasvir, Oncology, Glecaprevir, Voxilaprevir and Antibody.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
EASL Clinical Practice Guidelines: Management of chronic hepatitis B
C.P.G.P.P. Marcellin;G. Dusheiko;F. Zoulim;R. Esteban.
Journal of Hepatology (2009)
Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes.
Peter Simmonds;Jens Bukh;Christophe Combet;Gilbert Deléage.
EASL Recommendations on Treatment of Hepatitis C
Jean-Michel Pawlotsky;Alessio Aghemo;Geoffrey Dusheiko;Xavier Forns.
Journal of Hepatology (2018)
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
Christophe Hézode;Nicole Forestier;Geoffrey Dusheiko;Peter Ferenci.
The New England Journal of Medicine (2009)
Statements from the Taormina expert meeting on occult hepatitis B virus infection.
Giovanni Raimondo;Jean Pierre Allain;Maurizia R. Brunetto;Marie Annick Buendia.
Journal of Hepatology (2008)
Structural biology of hepatitis C virus
François Penin;Jean Dubuisson;Felix A. Rey;Darius Moradpour.
Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management.
Anna S. Lok;Fabien Zoulim;Stephen Locarnini;Angeline Bartholomeusz.
New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges
Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens.
Jean-Michel Pawlotsky;Jean-Michel Pawlotsky.
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890
Christophe Hézode;Hélène Fontaine;Céline Dorival;Dominique Larrey.
Journal of Hepatology (2013)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: